



# PHARMACOTHERAPY GUIDE

---

## JCC Santo Domingo 2026

**Versión:2.0 | Fecha:** 10 mayo del 2026

**Fechas del evento:** 24 de julio - 8 de agosto de 2026.

**Ubicación:** Santo Domingo, República Dominicana.



## SANTO DOMINGO 2026 ORGANIZING COMMITTEE

- Lic. José P. Monegro - *President*
- Lic. Felipe Vicini - *Vice President*
- Garibaldi Bautista, **Engineer** - *2nd Vice President*
- José Manuel Ramos, **Engineer** - *3rd Vice President*
- Kelvin Cruz, **Engineer** - *Secretary*
- Mercedes Canalda, **Esq.** - *Treasure*
- Carolina Mejía, **Esq.** - *Member*
- Eduardo Estrella, **Engineer** - *Member*
- Fernando Langa, **Esq.** - *Member*
- Lic. Frank Elías Rainieri - *Member*
- Carlos Iglesias, **Engineer** - *Member*
- Andrés Vanderhost - *Member*

## MEMBERS OF THE PHARMACY AND THERAPEUTICS COMMITTEE

- **Dr. Milton Pinedo Soriano** - *General Coordinator of Medical Services and Doping Control, Santo Domingo 2026*
- **Dr. Elías Pérez González** – *Coordinator of Medical Services, Santo Domingo 2026*
- **Dr. Laura Anabel Pinedo** – *Doping Control Coordinator, Santo Domingo 2026*
- **Dr. Lisette A. Sánchez** – *General Supervisor of Doping Control, Santo Domingo 2026*
- **Lic. Vilma Guerrero** – *Pharmaceutical Consultant, Santo Domingo 2026*
- **Dr. William Duke Torres** – *Specialist in Epidemiology*
- **Dr. Dionisio Guzmán** – *Specialist in Orthopedics and Traumatology*
- **Dr. Cesar Andrés Báez** – *Specialist in Internal Medicine and Gastroenterology*
- **Dr. Manuel Cuello Batista** – *Specialist in Orthopedics and Traumatology*
- **Dr. José Joaquín Núñez** – *Specialist in Orthopedics and Traumatology*
- **Dr. Víctor Figueroa** – *Physical Therapist*
- **Dr. Elíasiris Sánchez** – *General and Sports Physician*
- **Dr. Francis Reyes** – *General and Sports Physician*
- **Dr. Rovertto Morla** – *Specialist in Gynecology and Obstetrics*

## LEADERS OF THE MEDICAL SERVICES PROGRAM

- **Dr. Hans Larsen** - *Chair of the CCS Medical Commission*
- **Dr. José Joaquin Puello** - *Honorary Medical Advisor*
- **Dr. Julio Landron** - *Director of the National Health Service (SNS) and Honorary Medical Advisor*
- **Dr. Milton Pinedo S.** - *General Coordinator of Medical Services and Doping Control*
- **Dr. Elías Pérez González** - *Medical Coordinator*
- **Lic. Vilma Guerrero** - *Pharmaceutical Consultant*

# PRESENTATION



Distinguished members of Centro Caribe Sport (CCS), National Olympic Committees (NOCs), Heads of Mission, and participants in the Games:

As President of the **Santo Domingo 2026 Organizing Committee**, I express my commitment to fair play and the health of the stars of this event: the athletes.

**The Santo Domingo 2026 Therapeutic Drug Guide** is the official document governing the use of medications during the Games. Its objective is twofold:

**1. To safeguard health by providing a safe guide for the treatment of common injuries and illnesses during competition.**

**2. To ensure anti-doping compliance by guaranteeing that no medication provided by official medical services contains substances prohibited by WADA (World Anti-Doping Agency).**

In this document, our team of specialists has consolidated the pharmacological care protocols to be followed at each of the venues, hospitals, and polyclinics in the Athletes' Village. The following three key points stand out:

- ▶ Updates: Aligned with the Prohibited List in effect for 2026.
- ▶ Accessibility: Available digitally to all heads of mission and medical delegations from participating countries.
- ▶ Quality Control: The medications included have been selected under strict national and international pharmaceutical industry standards.

We want every delegation that visits us to be certain that, in the event of any medical emergency, Santo Domingo 2026's response will be scientific, ethical, and, above all, safe. We are leaving nothing to chance; this guide is the shield that protects the integrity of the competition and the future of our athletes.

**José P. Monegro**

President, Santo Domingo 2026 Organizing Committee.

# INDEX

I. INTRODUCTION.....	5
II. GENERAL INFORMATION ON THE RATIONAL USE OF MEDICATIONS .....	6
III. PRESCRIPTION AND DISPENSING OF MEDICATIONS.....	6
IV. MEDICATION PRESCRIPTION PROCEDURES .....	6
V. USE OF THE THERAPEUTIC DRUG GUIDE: .....	6
VI. LIST OF MEDICATIONS BY THERAPEUTIC GROUP: .....	7

## I. INTRODUCTION

Medical care in the sports field requires rigorous planning to ensure the safety, well-being, and peak performance of athletes. Within the framework of the 2026 Santo Domingo Central American and Caribbean Games, the development of a Pharmacotherapy Guide is essential to unify criteria, optimize resources, and ensure the rational and safe use of medications.

The purpose of this document is to serve as a reference for healthcare personnel responsible for the care of athletes during the competition, providing clear guidelines on the selection, indication, dosing, and administration of medications and products related to sports practice.

The guide is based on the selection of medications and medical supplies carried out by the Pharmacy and Therapeutics Committee, which is responsible for evaluating and selecting medications and supplies based on the National Essential Medicines List—which was reviewed by a team of specialized physicians—as well as on the recommendations of leading international organizations such as the World Health Organization (WHO), the World Anti-Doping Agency (WADA), and regional sports health regulations. It has also been developed considering the specific epidemiological, climatic, and logistical characteristics of the event.

Among its main objectives are:

- Ensuring the availability of essential medicines for emergency care and common sports-related conditions.
- To promote the rational use of medications, avoiding abuse or self-medication.
- Preventing risks related to substances prohibited by anti-doping regulations.
- Standardizing care protocols among the medical teams of the various participating countries.
- Strengthening patient safety and the quality of medical services during the games.

## II. GENERAL INFORMATION ON THE RATIONAL USE OF MEDICATIONS

As a complement to the Therapeutic Drug Guide, a Medication Information Center will be established within the pharmacy service at the La Villa JCC Polyclinic, which will provide details about the composition of international drugs and their national brand equivalents.

## III. PRESCRIPTION AND DISPENSING OF MEDICATIONS.

All accredited participants of the NOCs have access to the medication prescribed to them by physicians authorized by the Organizing Committee. Volunteers and support staff, as well as spectators, have free coverage for emergency medication.

## IV. MEDICATION PRESCRIPTION PROCEDURES

Medications will be dispensed at the pharmacy of the La Villa JCC Polyclinic from 8:00 a.m. to 9:00 p.m.

## V. USE OF THE THERAPEUTIC DRUG GUIDE:

Medications are classified by therapeutic group; this information includes:

1. Generic name or International Nonproprietary Name (INN).
2. Form, composition, concentration, and route of administration.
3. All drug indications will be validated against the World Anti-Doping Agency (WADA) Prohibited List – 2026.
4. The Pharmacotherapeutic Guide contains 23 therapeutic groups and 143 medications.

## VI. LIST OF MEDICATIONS BY THERAPEUTIC GROUP:

### CHAPTER 1

Anesthetics

### CHAPTER 2

Analgesics, antipyretics, NSAIDs, antigout agents, and antirheumatic agents

### CHAPTER 3

Antiallergics and Medications for Anaphylaxis

### CHAPTER 4

Antidotes and substances used in cases of poisoning

### CHAPTER 5

Antiepileptics, anticonvulsants

### CHAPTER 6

Anti-infective drugs

### CHAPTER 7

Migraine medications

### CHAPTER 8

Immunosuppressants

### CHAPTER 9

Medications that affect the blood

### CHAPTER 10

Cardiovascular medications

### CHAPTER 11

Dermatological medications

### CHAPTER 12

Disinfectants and Antiseptics

### CHAPTER 13

Diuretics

### CHAPTER 14

Medications for Gastrointestinal Conditions

## **CHAPTER 15**

Hormonal, Endocrine, and Contraceptive Medications

## **CHAPTER 16**

Immunological

## **CHAPTER 17**

Psychotropic Drugs

## **CHAPTER 18**

Medicines Acting on the Respiratory Tract

## **CHAPTER 19**

Solutions for Correcting Water, Electrolyte, and Acid-Base Imbalances

## **CHAPTER 20**

Vitamins, minerals, and bone disorders

## **CHAPTER 21**

Otolaryngological Preparations

## **CHAPTER 22**

Drugs for genitourinary disorders

ATC	ACTIVE INGREDIENT	FORM
<b>1. ANESTHETICS</b>		
N01BB01	Bupivacaine hydrochloride	Injection: 0.25% in vials
N01BB01	Bupivacaine hydrochloride	Injection: 0.5% in vials
N01BB01	Bupivacaine hydrochloride	Injection: 0.75% in vials
N01BB51	Bupivacaine hydrochloride + glucose	Injection for spinal anesthesia: 0.5%
D04AB01	Lidocaine hydrochloride	Topical forms: 2% to 4%
D04AB01	Lidocaine hydrochloride	Topical spray formulation: 10%
N01BB02	Lidocaine hydrochloride	Injection: 1% in vials
N01BB02	Lidocaine hydrochloride	Injection: 2% in vials
A03BA01	Atropine sulfate	Injection: 1 mg in 1-ml ampoules
N05CD08	midazolam	Tablet: 15 mg
N05CD08	midazolam	Injection: 5 mg/mL
N05BA01	diazepam	Tablet: 5 mg
<b>2. ANALGESICS, ANTIPYRETICS, NSAIDs, ANTITUSSIVES, AND ANTI-RHEUMATIC AGENTS</b>		
N02BE01	acetaminophen (paracetamol)	Tablet: 500 mg
N02BE01	acetaminophen	Injection 10 mg/mL in vial
B01AC06	Acetylsalicylic acid	Tablet: 325 mg
B01AC06	Acetylsalicylic acid	Tablet: 500 mg
M01AB05	Sodium diclofenac	Tablet: 50 mg
M01AB05	Diclofenac sodium	Injection: 25 mg/mL in a 3-mL ampoule
M01AE01	Ibuprofen	Tablet: 600 mg
M01A02.		
	<b>Naproxen</b>	<b>500 mg capsule or tablets</b>
	<b>Ketorolac tromethanol</b>	<b>Injection, 30 mg/mL</b>
<b>3. ANTALLERGICS</b>		
R06AX13	Loratadine	Tablet: 10 mg
R06AE07	Cetirizine	Tablet: 10 mg
	<b>Diphenhydramine</b>	<b>Ampoule/ 2 ml</b>
	<b>Hydroxyzine</b>	<b>Tablets 10 mg</b>
<b>4. ANTIDOTES AND SUBSTANCES USED IN POISONING</b>		
A07BA01	Activated charcoal	Powder in bottle: 50 g

## 5. ANTIEPILEPTICS, ANTICONVULSANTS

N03AG01	Valproic acid (sodium valproate)	Oral solution: 200 mg/mL
N05BA01	Diazepam	Injection: 5 mg/mL
N03AA02	Sodium phenobarbital	Injection: 200 mg/mL
B05XA05	Magnesium sulfate	Injection: 500 mg/mL in 2-mL ampoules
N03AX16	Pregabalin	Capsules or tablets: 300 mg

## 6. ANTI-INFECTIVE DRUGS

P02CA03	Albendazole	400 mg tablet
J01CA04	Amoxicillin as trihydrate	Capsules or Tablets: 500 mg
J01CR02	Amoxicillin + clavulanic acid	Tablet: 500 mg + 125 mg
J01CE08	Benzathine benzylpenicillin	Powder for Injection: 600,000 IU in vials
J01CE08	benzathine benzylpenicillin	Powder for injection: 900 mg of benzylpenicillin (= 1.2 million IU) in 5-ml vials
J01CE08	benzathine penicillin G	Powder for injection: 1.44 g of benzylpenicillin (= 2.4 million IU) in 10-ml vials
J01CE09	procaine penicillin G (benzylpenicillin procaine)	Powder for injection: 400,000 IU in vials
J01DB01	Cephalexin monohydrate	Tablet: 500 mg
J01FA10	Anhydrous azithromycin	Capsules: 500 mg
J01FA01	erythromycin as stearate, stearate, or ethylsuccinate	Tablet: 500 mg
J01AA02	doxycycline hydrate or monohydrate	Oral solid form or capsules: 100 mg
J01EE01	sulfamethoxazole + trimethoprim	Tablet: 400 mg + 80 mg
J02AC01	fluconazole	Capsules: 150 mg
A01AB91	Nystatin	Vaginal suppositories: 100,000 IU
J01FF01	clindamycin	Vaginal ovules: 100 mg
G01AF02	Clotrimazole	Vaginal ovules: 500 mg
D01AC08	ketoconazole	Topical cream: 2%
J05AB01	acyclovir	Ointment: 3% w/w
J05AB01	acyclovir	Tablet: 400 mg
J01XD01	metronidazole	Tablet: 500 mg
P01AB51	metronidazole + diiodohydroxyquinoline	Tablet: 400 mg + 200 mg

J01XD02	tinidazole	Tablet: 500 mg
	Metronidazole	Vaginal suppository
<b>7. ANTIMIGRAINE MEDICATIONS</b>		
B01AC06	Acetylsalicylic acid	Tablet: 500 mg
N02BE01	Acetaminophen	Tablet: 500 mg
N02CC01	Sumatriptan	Tablet: 50 mg
N02CA02	Ergotamine tartrate	Tablet: 1 mg
<b>8. ANTIEMETIC MEDICATIONS</b>		
A03FA01	Metoclopramide hydrochloride	Tablet: 10 mg
A03FA01	Metoclopramide hydrochloride	Injection: 5 mg/mL in 2-mL vials
<b>9. DRUGS AFFECTING THE BLOOD</b>		
B03AD03	Ferrous sulfate + folic acid + vitamin C	Tablets: 300 mg, 0.4 mg of folic acid, and 40 mg of vitamin C
B03BA03	Hydroxocobalamin	Injection: 1 mg in 1-ml vials
B01AB01	Sodium heparin	Injection: 5,000 IU/ml in a vial
B01AA03	Warfarin sodium	Tablet: 2 mg
<b>10. CARDIOVASCULAR DRUGS</b>		
C01DA02	Nitroglycerin	Injection: 5 mg/5 ml
C01DA02	Glyceryl trinitrate	Tablets (sublingual): 500 µg
C01BC03	Propafenone	Tablet: 150 mg
A03BA01	Atropine sulfate	Injection: 1 mg in 1-ml vials
C01BB01	lidocaine hydrochloride	Injection: 20 mg/ml in 5-ml ampoules
C01CA24	epinephrine (adrenaline) as tartrate or hydrochloride	Injection: 100 µg/mL, in 10-mL ampoules
C07AB03	Atenolol	Tablet: 100 mg
C09CA01	Losartan	Tablet: 50 mg
C09BB03	Lisinopril + amlodipine	Tablets: 20 mg + 10 mg
C09BA03	lisinopril + hydrochlorothiazide	Tablets: 20 mg + 12.5 mg
C09BA03	lisinopril + hydrochlorothiazide	Tablets: 20 mg + 25 mg
C09CA03	valsartan	Tablets: 320 mg
C09CA04	irbesartan	Tablet: 150 mg
C08CA05	nifedipine	Extended-release tablets: 30 mg
C03AA03	hydrochlorothiazide	Tablet: 50 mg
B01AC06	acetylsalicylic acid	Tablet: 81 mg

B01AC04	clopidogrel	Tablet: 75 mg
B01AD01	streptokinase	Powder for injection: 1.5 million IU in vials.
C10AA05	atorvastatin	Tablets: 20 mg
<b>11. DERMATOLOGICAL DRUGS</b>		
A01AB91	Nystatin	Vaginal ovules: 100,000 IU
G01AF02	Clotrimazole	Solid or cream: 1%
G01AF02	Clotrimazole	Vaginal tablets: 500 mg
D08A	Oatmeal soap	Paste: 100 g
D08AF01	Nitrofurazone	Cream: 0.2%
D02AB	zinc oxide	Lotion
D04AX00	calamine	Lotion
D10AE01	benzoyl peroxide	Cream or lotion: 5%
D06BB04	Podophyllin resin	Solution: 10% 25%
D02AF00	salicylic acid	Solution: 5%
D02AE01	urea	Cream or ointment: 5%
P03AC04	permethrin	Lotion: 5%
P03AC04	permethrin	Shampoo: 1%
<b>12. DISINFECTANTS AND ANTISEPTICS</b>		
V03AB16	Isopropyl alcohol	Solution: 70%
D08AX00	Glutaraldehyde	Solution: 2%
<b>13. DIURETICS</b>		
C03AA03	Hydrochlorothiazide	Tablet: 25 mg
C03AA03	Hydrochlorothiazide	Tablet: 50 mg
C03CA01	Furosemide	Tablet: 40 mg
C03CA01	Furosemide	Injection: 10 mg/mL in 2-mL vials
<b>14. MEDICINES FOR GASTROINTESTINAL DISORDERS</b>		
A02BA02	Ranitidine as hydrochloride	Tablet: 150 mg
A02BA02	Ranitidine as hydrochloride	Injection: 25 mg/mL in 2-mL vials
A02BC01	Omeprazole	Capsule: 40 mg
A02BC01	Omeprazole	Injection: 40 mg
A03FA01	Metoclopramide hydrochloride	Tablet: 10 mg
A03FA01	Antacids	Chewable tablets
A03FA01	Metoclopramide hydrochloride	Injection: 5 mg/mL in 2-mL vials
D04AB01	tribenoside + lidocaine	Cream or suppository: (5 g + 100 g)

A03BA01	atropine sulfate	Injection: 1 mg in 1-ml vials
A03BA03	butylhyoscine	Tablet: 10 mg
A03BA03	hyoscine butylbromide	Injection: 20 mg/mL
A06AD11	lactulose	Solution: 3.33 g/5 ml
A07CA00	oral rehydration salts with citrate	Powder for solution: 200 ml; 500 ml; 1 liter.
A07DA03	loperamide	Tablet: 2 mg

### 15. HORMONAL, ENDOCRINE, AND CONTRACEPTIVE DRUGS

H02AB02	Dexamethasone	Tablet or capsule: 0.5 mg
H02AB02	Dexamethasone	Tablet or capsule: 0.75 mg
H02AB02	Dexamethasone	Tablet or capsule: 4 mg
H02AB02	Dexamethasone phosphate as disodium salt	Injection: 4 mg/mL in 1-mL vials
H02AB07	Prednisone	Tablet: 5 mg
H02AB07	Prednisone	Tablet: 20 mg
H02AB07	Prednisone	Tablet: 50 mg
G02BB00	male condom	Unit
A10BK01	dapagliflozin	Tablets: 10 mg
A10BA02	metformin	Tablet: 850 mg
A10BA02	metformin	Tablet: 500 mg
A10BD01	metformin + glibenclamide	Tablet: 1,000 mg/5 mg Tablet: 500 mg/2.5 mg
A10AC01	Intermediate-acting insulin NPH	Injection: 40 IU/mL in a 10-mL vial; (as a compound suspension of zinc insulin or isophane insulin)
A10AC01	Intermediate-acting insulin NPH	Injection: 40 IU/mL in 10 ml; 100 IU/ml in 10 ml vials (as a suspension of zinc insulin or isophane insulin)

### 16. IMMUNOLOGICALS

J06BB02	Tetanus antitoxin (Human)	Injection: 1,500 IU
---------	---------------------------	---------------------

### 17. OPHTHALMOLOGICAL PREPARATIONS

S01AA11	Gentamicin sulfate	Solution (eye drops): 0.3%
S01AA09	Tetracycline hydrochloride	Ophthalmic ointment: 1%
S01AA01	Chloramphenicol	0.5% eye drops
S01AA12	Tobramycin	Ophthalmic ointment 3.5g
S01AA12	tobramycin	Solution (eye drops): 0.3%
S01AD03	acyclovir	Ointment: 3% w/w

## 18. PSYCHOPHARMACOLOGIC AGENTS

<b>N05AD01</b>	Haloperidol	Tablet: 2 mg
<b>N05AD01</b>	Haloperidol	Tablet: 5 mg
<b>N05AX08</b>	Risperidone	Tablet: 1 mg
<b>N05AX08</b>	Risperidone	Tablet: 2 mg
<b>N06AA09</b>	Amitriptyline hydrochloride	Tablet: 25 mg
<b>N06AA04</b>	clomipramine hydrochloride	Capsules: 10 mg

## 19. DRUGS ACTING ON THE RESPIRATORY TRACT

<b>C01CA24</b>	Epinephrine	Injection: 1 mg in 1-ml vials
<b>R03DA05</b>	Aminophylline	Injection: 25 mg/ml, 10 ml
<b>R01AD01</b>	Beclomethasone dipropionate	Inhalation (aerosol): 50 µg per dose (in CFC-free formulations)
<b>R03AC02</b>	salbutamol sulfate	Solution for use in nebulizers: 5 mg/mL
<b>R03AC02</b>	Salbutamol sulfate	Inhalation (aerosol): 100 µg per dose

## 20. SOLUTIONS FOR CORRECTING WATER, ELECTROLYTE, AND ACID-BASE DISORDERS

<b>A07CA00</b>	Oral Rehydration Salts with Citrate	Powder for solution: 200 mL; 500 mL; 1 liter.
<b>B05BA03</b>	Glucose (dextrose)	Solution for injection: 5% (isotonic) in 500 ml and 1 L
<b>B05BA03</b>	Glucose (dextrose)	Solution for injection: 10% (hypertonic) 500 ml and 1 L
<b>B05BA03</b>	Glucose (dextrose)	Solution for injection: 50% (hypertonic) in 20 mL, 500 mL, and 1 L
<b>V07AB00</b>	Water for injection	Injection: 5 ml
<b>V07AB00</b>	Water for injection	Injection: 10 ml

## 21. VITAMINS, MINERALS, BONE DISORDERS

<b>A11CA01</b>	Retinol (vitamin A)	Tablets: 200,000 IU
<b>A11CC01</b>	Ergocalciferol (vitamin D)	Oral solid form: 1.25 mg (50,000 IU)
<b>A11GA01</b>	ascorbic acid (vitamin C)	Tablet: 500 mg
<b>A11DA01</b>	thiamine (vitamin B1) hydrochloride	Tablet: 50 mg
<b>B03BA03</b>	Hydroxocobalamin (vitamin B12) as acetate, hydrochloride, or sulfate	Injection: 1 mg in 1-ml vials
<b>A11HA03</b>	Vitamin E	Capsule: 400 mg

## 22. OTORHINOLARYNGOLOGICAL PREPARATIONS

R01AD05	Budesonide	Nasal spray: 100 µg per dose
S01GA03	Xylometazoline	Nasal spray: 0.05%

## 23. DRUGS FOR GENITOURINARY DISORDERS

G04CB01	Finasteride	Tablet: 5 mg
G04BD04	Oxybutynin hydrochloride	Tablet: 5 mg

